Melax Tech, a Houston-based natural language processing (NLP) tech firm, announced a sponsorship agreement with BioSpark Group, based in Cambridge, Massachusetts. In the biomedical field, BioSpark facilitates scientific translation by building a network of scholars and entrepreneurs. In the life sciences and biomedical domains, Melax Tech is known for its award-winning work in-text annotation and extraction.
Andre Pontin, CEO of Melax Tech, said, “The relationship between Melax Tech and BioSpark Group comes naturally, as both the group’s members and our company are invested in improving the quality of healthcare and care reporting, and breakthroughs in pharma and medicine. We look forward to showcasing our software capabilities in educational programs to BioSpark members during the coming year.”
With this affiliation, Melax Tech expects to enhance its capabilities in unstructured text data extraction and normalization in biopharmaceutical R&D applications, as members in BioSpark’s community can access Melax Tech’s CLAMP framework and explore the technology’s utility.
